News

Trial of QRL-201, Aiming to Slow ALS Progression, Opening in Canada

Health Canada has given a green light to QurAlis‘ request to open a Phase 1 clinical trial of QRL-201, its candidate antisense oligonucleotide (ASO) molecule to protect and repair nerve cells, slowing disease progression, in people with amyotrophic lateral sclerosis (ALS). The global trial, called ANQUR (NCT05633459), will…

Low-dose Aldesleukin Slows ALS Progression, Extends Survival: Trial

A low dose of aldesleukin, an immunotherapy approved for certain cancers, slowed disease progression and significantly improved survival in people with amyotrophic lateral sclerosis (ALS), particularly in those with less aggressive disease. These are the most recent results from the MIROCALS Phase 2 trial (NCT03039673), which tested aldesleukin…

DNL343 Well-tolerated by ALS Patients, Interim Data Show

DNL343, an investigational oral small molecule developed by Denali Therapeutics, can extensively enter the brain and reduce the cellular stress response that contributes to amyotrophic lateral sclerosis (ALS) progression. That’s according to an interim analysis of data from a Phase 1b clinical trial (NCT05006352), in which DNL343 was…

Northeast Community PTA Students Raise $1,200+ for ALS Research

For the last 15 years, students in the physical therapy assistant (PTA) program at Northeast Community College in Norfolk, Nebraska have participated in a local amyotrophic lateral sclerosis (ALS) event that seeks to raise awareness about the progressive neurodegenerative disorder — and raise the funds to fight it. This…

New Deal Helps Move Gene Therapy ET-101 Closer to Clinical Testing

Eikonoklastes Therapeutics and Forge Biologics have announced a new partnership to advance the development of ET-101, an experimental gene therapy for amyotrophic lateral sclerosis (ALS), toward clinical trial testing. Eikonoklastes acquired the rights to ET-101 from the University of California San Diego earlier this year. Under…

Analyses Support Design of COURAGE-ALS Trial of Reldesemtiv 

The COURAGE-ALS Phase 3 clinical trial, testing Cytokinetic’s experimental therapy reldesemtiv in people with amyotrophic lateral sclerosis (ALS), is expected to enroll patients who are most likely to benefit from the potential treatment. That’s according to a new analysis of data from an earlier Phase 2 study of reldesemtiv called…

Effector T-cell Levels May Predict Disease Progression, Survival

Higher levels of inflammatory immune cells called effector T-cells at the time of diagnosis are associated with faster disease progression and worse survival among people with amyotrophic lateral sclerosis (ALS), a new study indicates. In turn, greater numbers of regulatory T-cells, which work to dampen excessive immune responses, were…